Abstract
This article discusses the potential usefulness of clinical therapeutic trials and criticises the failure of the value of guidelines in the management of osteoarthritis (OA). We have provided an overview of the benefits and side effects of non steroidal anti-inflammatory drugs (NSAIDs) in OA, including the introduction of the COX-2 selective inhibitors. In addition we have briefly reviewed the use of local NSAIDs, narcotic analgesics, injection methods, disease modifying drugs, gene therapy, surgical treatment, and non pharmacological intervention.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Abernethy, D. R., Diroll, M., Ochs, H. R., et al. (1982). Increased metabolic clearance of aceta-minophen with oral contraceptive use, Obst. Gynecol. 60, 338–341.
Abernethy, D. R., Ameer, B. and Greenblatt, D. J. (1984). Probencid inhibition of acetaminophen and lorazepamglucuronidation, Clin. Pharmacol. Ther. 35, 224.
Acevedo, E., Romanowicz, A., Van der Heyde, D., et al. (1999). Rofecoxib, a COX-2 specific inhibitor (C-251), had a clinical efficacy comparable to diclofenac on the treatment of knee and hip osteoarthritis (OA) in a one-year controlled trial, Ann. Rheum. Dis. (EULAR), p. 206, Abstract 858.
Adams, M. E. (1993). An analysis of clinical studies of the use of cross-linked hyaluronan–hylan in the treatment of osteoarthritis, J. Rheumatol. 22 (Suppl. 39), 15–17.
Adams, M. E., Atkinson, M. H., Lussier, A. J., et al. (1995). The role of viscosupplementationwith hylan G-F20 (Synvisc ® ) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial company hylan G-F20 alone, hylan G-F20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone, Osteoarthritis and Cartilage 3, 213–225.
Agrawal, N., Paperiello, B., Zhao, W. W., et al. (2001). Supratherapeutic doses of valdecoxib have a reduced incidence of gastroduodenal ulcers compared with conventional therapeutic doses of naproxen in osteoarthritis and rheumatoidarthritis patients, Arthritis Rheum. 44 (Suppl. 9), abstract 1917, S372.
Alarcon-Segovia, T. (1980). Long-term treatment of symptomatic osteoarthritis with benoxaprofen. Double blind comparison with aspirin and ibuprofen, J. Rheum. 6 (Suppl.), 89–99.
Allman, R. D. and Hochberg, M. C. (1983). Degenerative joint disease, in: Clinical Trials in the Rheumatic Diseases, J. H. Klippel and J. L. Decker (Eds). W. B. Saunders, Philadelphia, Clin. Rheum. Dis. 9, 681–693.
Altman, R. D. (1984). Review of ibuprofen for osteoarthritis, Am. J. Med. 77, 10–18.
Altman, R. D. (1990). ARC Subcommittee on classification criteria of osteoarthritis: the American College of rheumatology criteria for the classification and reporting of osteoarthritis of the hand, Semin. Arthritis Rheum. 33, 1601–1610.
Altman, R. D. (1997). The syndrome of osteoarthritis, J. Rheumatol. 24, 766–767.
Altman, R. D. and Moskowitz, R. (1998). Intra-articular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial, J. Rheumatol. 25, 2203–2212.
Altman, R. D., Asch, E., Blich, D., et al. (1986). Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee, Semin. Arthritis Rheum. 29, 1039–1049.
Altman, R. D., Alarcón, G., Appelrouth, D., et al. (1991). The American College of Rheumatology Criteria for the classification and reporting of osteoarthritis of the hip, Arthritis Rheum. 34, 505–514.
Altman, R. D., Hochberg, M. C., Moskowitz, R., et al. (2000). Recommendations for the medical management of osteoarthritis of the hip and knee. 2000 update. American College of Rheumatol-ogy subcommittee on osteoarthritis guidelines, Arthritis Rheum. 43, 1905–1915.
Amadio, P. J. and Cummings, D. M. (1983). Evaluation of acetaminophen in the management of osteoarthritis of the knee, Curr. Ther. Res. 34, 59–66.
Amadio, P. Jr., Cummings, D. M. and Amadio, P. (1993). Nonsteroidal anti-inflammatory drugs. Tailoring therapy to achieve results and avoid toxicity, Postgrad. Med. 93, 73–76, 79–81, 85–88.
American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. (2000). Recommen-dations for the medical management of osteoarthritis of the hip and knee. 2000 Update, Arthritis Rheum. 43, 1905–1915.
American Pain Society Quality of Care Committee. (1995). Quality improvement guidelines for the treatment of acute pain and cancer pain, JAMA 274, 1874–1880.
Anderson, J. J., Firschein, H. E. and Meeman, R. F. (1989). Sensitivity of a health status measure to short-termclinical changes in arthritis, Arth. Rheum. 32, 844–850.
Andrade, L. and Fernandez, A. (1978). Sulindac in the treatment of osteoarthritis: a double-blind, 8-week study comparing sulindac with ibuprofen and 96 weeks of long-term therapy, Europ. J. Rheum. Inflamm. 1, 36–40.
Antlitz, A. M. and Awalt, L. F. (1969). A double blind study of acetaminophen used in conjunction with oral anticoagulant therapy, Curr. Ther. Res. 11, 360–361.
Antlitz, A. M., Mead, J. A. and Tolentino, M. A. (1968). Potentiation of oral anticoagulant therapy by acetaminophen, Curr. Ther. Res. 10, 501–507.
Appelrouth, D. J., Baim, S., Chang, R. W., et al. (1987). Comparison of the safety and efficacy of nabumetone and aspirin in the treatment of osteoarthritis in adults, Am. J. Med. 83, 78–81.
Avila, M. H., Walker, A. M., Romieu, I., et al. (1988). Choice of non-steroidal anti-inflammatory drug in persons treated with dyspepsia, Lancet 2, 556–559.
Ayral, X., Dourados, M., Listrat, V., et al. (1993). Chondroscopy: a new method for scoring chondropathy, Semin. Arthritis Rheum. 22, 289–297.
Badley, E. M. (1995). The effect of osteoarthritis on disability and health care use in Canada, J. Rheumatol. 22, 19–22.
Badley, E. M. and Wang P. P. (1998). Arthritis and the ageing population: projections of arthritis prevalence in Canada 1991 to 2031, J. Rheumatol. 25, 138–144.
Badley, E. M. and Williams, J. I. (Eds). (1998). Patterns of Health Care in Ontario: Arthritis and Related Conditions: on ICES practice atlas. Toronto Institute for Clinical Evaluative Sciences, pp. 98–101.
Balazs, E. A. and Denlinger, J. L. (1993). Viscosupplementation: a new concept in the treatment of osteoarthritis, J. Rheumatol. Suppl. 39, 3–9.
Balazs, L., Lohmander, L. S. and Ryd, L. (1994). Intra-articular injections of hyaluronan in patients with cartilage abnormalities and knee pain. A one year double-blind, placebo-controlled study, Arthritis Rheum. 37, 521–528.
Barnard-Jones, K., Davis, R. W., Lalla, O., et al. (1986). Mefenamic acid versus ibuprofen in osteoarthritis — a double-blind crossover study, Br. J. Clin. Prac. 40, 528–531.
Bartle, W. R. and Blakely, J. A. (1991). Potentiation of warfarin anticoagulation by acetaminophen, JAMA 265, 1260.
Bell, W. R. (1998). Acetaminophen and warfarin: an undesirable synergy, J. Amer. Med. Assoc. 279, 702–703.
Bellamy, N. (1993). Musculoskeletal Clinical Metrology, Chapter 14, pp. 169–176. Kluwer Academic Publishers, Dordrecht.
Bellamy, N. and Buchanan, W. W. (1997). Clinical evaluation in rheumatic diseases, in: Arthritis and Allied Conditions. A Textbook of Rheumatology, 13th edn, W. J. Koopman (Ed.), Vol. 1., pp. 47–79. Williams and Wilkins, Baltimore.
Bellamy, N. and Buchanan, W. W. (2000). Clinical evaluation in the rheumatic diseases, in: Arthritis and Allied Conditons. Textbook of Rheumatology, 13th edn, W. J. Koopman (Ed.) Vol. 1, pp. 51–82. Williams and Wilkins, Baltimore, Maryland.
Bellamy, N., Buchanan, W. W., Goldsmith, C. H., et al. (1988). Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to anti-rheumatic drug therapy in patients' osteoarthritis of the hip or knee, J. Rheumatol. 15, 1833–1840.
Bellamy, N., Kirean, J., Boers, M., et al. (1997). Recommendations for a core set of outcomemeasures for future phase III clinical trials in knee, hip and hand osteoarthritis. Consensus development at OMERACT III, J. Rheumatol. 24, 799–802.
Bellville, J. W., Forrest, W. H., Miller, E., et al. (1971). Influence of age on pain relief fromanalgesics, J. Am. Med. Assoc. 217, 1835–1841.
Bennett, P. and Slater, D. (1996). Cox-2 expression in labour, in: Improved Non-steroid Anti-infl ammatory Drugs. COX-2 Enzyme Inhibitors, Vane, J., Botting, J., Botting, R. (Eds), pp. 167–168. Kluwer Academic Publishers, Lancaster, and William Harvey Press, London.
Bensen, W. G., Fiechtner, J. J., McMillen, J. I., et al. (1999). Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2inhibitor: a randomized controlled trial, Mayo. Clin. Proc. 74 (11), 1095–1105.
Berkowitz, B. A., Ngai, S. H., Yang., J. C. et al. (1975). The disposition of morphine in surgical patients, Clin. Pharmacol. 17, 629–634.
Berman, B. M., Singh, B., Lao, L., et al. (1999). A randomized trial of acupuncture as a adjunctive therapy in osteoarthritis of the knee, Rheumatology 38, 346–354.
Berndt, S., Maier, C. and Schütz., H. W. (1993). Polymedication and medication compliance in patients with chronic non-malignant pain, Pain 52, 331–339.
Blackshear, J. L., Napier, J. S., Davidman, M., et al. (1995). Renal complications on nonsteroidal anti-inflammatory drugs: identification and monitoring of these at risk, Sem. Arthritis Rheum. 14, 163–175.
Boardman, P. L., Nuki, G. and Hart, F. D. (1967). Ibuprofen in the treatment of rheumatoid arthritis and osteo-arthritis, Ann. Rheum. Dis. 26, 560–561.
Bolten, W. (1994). The pharmacokinetics, pharmacodynamics and comparative efficacy of flurbipro-fen, LAT, Br. J. Clin. Pract. 48, 190–195.
Bombardier, C., Laine, L., Reicin, A., et al. (2000). Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. The VIGOR study group, New Engl. J. Med. 343, 1520–1528.
Botting, R. (2000). Paracetamol-inhibitableCOX-2, J. Physiol. Pharmacol. 51 (4, Pt 1), 609–618.
Bradley, J. D., Brandt, K. D., Katz., B. P., et al. (1991). Comparison of an anti-inflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee, New Engl. J. Med. 325, 87–91.
Bradley, J. D., Rudy A. C., Katz, B. P., et al. (1992a). Correlationof serum concentrationsof ibuprofen sterioisomers with clinical response in the treatment of hip and knee osteoarthritis, J. Rheumatol. 19, 130–134.
Bradley, J. D., Brandt, K. D., Katz, B. P., et al. (1992b). Treatment of knee osteoarthritis: Relationship of clinical features of joint inflammation to the response to a nonsteroidal anti-inflammatory drug or pure analgesic, J. Rheumatol. 19, 1950–1954.
Brandt, K. D. (1993a). Should osteoarthritis be treated with nonsteroidal anti-inflammatory drugs?, Rheum. Dis. Clin. North Amer. 19, 29–44.
Brandt, K. D. (1993b). Should non-steroidal anti-inflammatory drugs be used to treat osteoarthritis?, Rheum. Dis. Clin. North Amer. 19, 697–712.
Brandt, K. D. (1993c). NSAIDs in the treatment of osteoarthritis. Friends or foes?, Bull. Rheum. Dis. 42, 1–4.
Brandt, K. D. (2001). A critique of the 2000 update of the American College of Rheumatology recommendationsfor management of hip and knee osteoarthritis, Arthritis Rheum. 44, 2451–2455.
Brandt, K. D. and Palmoski, M. J. (1984). The effects of salicylates and other nonsteroidal anti-infl ammatory drugs on articular cartilage, Am. J. Med. 77, 65–69.
Brandt, K. D. and Schumacher, H. R. Jr. (1995). Osteoarthritis and crystal deposition diseases, Curr. Opin. Rheumatol. 7, 343–345.
Breder, C. D., Dewitt, D. and Kraig, R. P. (1995). Characterizationof inducible cyclooxygenase in rat brain, J. Comp. Neurol. 355, 296–315.
Bresnihan, B., Hughes, G. and Essigman, W. K. (1978). Diflunisal in the treatment of osteoarthritis: a double-blind study comparing diflunisal with ibuprofen, Curr. Med. Res. Opin. 5, 556–561.
Brideau, C., Kargmans, S., Liu, S., et al. (1996). A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitor, Inflamm. Res. 45, 68–74.
Brodie, N. H., McGhie, R. L., O'Hara, H., et al. (1980). Fenclofenac and ibuprofen in the treatment of osteoarthritis, Br. J. Clin. Prac. 34, 334–336.
Brooke, J. W. (1976). Fenoprofen therapy in large joint osteoarthritis: double-blind comparison with aspirin and long-term experience, J. Rheum. 3 (Suppl), 71–75.
Brooks, P. M. and Buchanan, W. W. (1991). Predication of the clinical efficacy of and intolerance to anti rheumatic drug therapy, in: Prognosis in the Rheumatic Diseases, N. Bellamy (Ed.), pp. 347–402. Kluwer Academic Publishers, Lancaster, England.
Brooks, P. M. and Day, R. O. (1991). Non-steroidal anti-inflammatory drugs: differences and similarities, New Engl. J. Med. 324, 1716–1725.
Brooks, P. M., Dougan, M. A., Mugford, A., et al. (1982). Comparative effectivenessof five analgesics in patients with rheumatoid arthritis and osteoarthritis, J. Rheumatol. 9, 732–736.
Brooks, P., Emery, P., Evans, J. F., et al. (1999). Interpretingthe clinical significance of the differential inhibition of cyclooxygenase-1and cyclooxygenase-2, Rheum. 38, 779–788.
Buchanan, W. W. and Bellamy, N. (1992). The controlled clinical trial: the gold standard with clay feet, in: Rheumatology: State of the Art, G. Balint, B. Yomov, L. Hodinka (Eds), pp. 229–301. Excerpta Medica, Amsterdam.
Buchanan, W. W. and Brooks, P. M. (1991). Prediction of organ system toxicity with anti rheumatic drug therapy, in: Prognosis in the Rheumatic Diseases, N. Bellamy (Ed.), pp. 403–450. Kluwer Academic Publishers, Lancaster, England.
Buchanan, W. W. and Kean, W. F. (1987). Current nonsteroidal anti-inflammatory drug therapy in rheumatoid arthritis, with an emphasis in the elderly, Nonsteroidal Anti-inflammatory DrugsDe s, Chap. 2, pp. 9–29. Marcel Dekker, New York.
Buchanan, W. W. and Kean, W. F. (2001). Evidence based medicine: the median is not the message, J. Rheumatol. 28, 2371–2372.
Buchanan, W. W. and Kean, W. F. (2002). OA II: Pathology and pathogenesis, Inflammopharmacology 10, 23–52.
Buckland-Wright, J. C. (1994). Quantitative radiography of osteoarthritis, Ann. Rheum. Dis. 53, 268–275.
Buckland-Wright, J. C., McFarlane, D. G., Lynch, J. A., et al. (1995a). Joint space width measures cartilage thickness in osteoarthritis of the knee: high resolution plain film and double contrast macroradiographic investigation, Ann. Rheum. Dis. 54, 263–268.
Buckland-Wright, J. C., McFarlane, D. G., Lynch, J. A., et al. (1995b). Quantitative microfocal radiography detects changes in OA knee joint space width in patients in placebo controlled trial of NSAID therapy, J. Rheumatol. 22, 937–943.
Buckwalter, K. A. (1993). Imaging in OA and crystal deposition diseases, Curr. Opin. Rheumatol. 5, 503–509.
Bueijinga, J. J., Boerstra, E. E., Ris, P., et al. (1982). Interaction between paracetamol and coumadin anticoagulants, Lancet 1, 506.
Bunting, S., Moncada, S. and Vane, J. R. (1983). The prostacyclin–thromboxane balance: pathophys-iological and therapeutic considerations, Br. Med. Bull. 39, 271–276.
Bunyaratavej, N., Keorochana, S. and Pithkul, S. (2001). Sefety and efficacy of meloxicam 7.5 mg in the treatment of osteoarthritis in Thai patients, J. Med. Assoc. Thai. 84, s542–546.
Busson, M. (1986). Update on ibuprofen: review article, J. Int. Med. Res. 14, 53–62.
Caldwell, J. R., Crain, D., Hoffmeister, R. T., et al. (1983). Four-way multicentre, crossover trial of ibuprofen, fenoprofen calcium, naproxen and tolmetin sodium in osteoarthritis: comparative clinical profiles, Southern. Med. J. 76, 706–711.
Caldwell, J. R., Hale, M. E., Boyd, R. E., et al. (1999). Treatment of osteoarthritis pain with con-trolled release oxycodone or fixed combination oxycodone plus acetaminophen added to non-steroidal anti-inflammatory drugs: a double-blind, randomized, multicenter, placebo-controlled trial, J. Rheumatol. 26, 862–869.
Callahan, C. M., Drake, B. G., Heck, D. A., et al. (1994). Patient outcomes following tricompartmen-tal total knee replacement. A meta-analysis, J. Am. Med. Assoc. 271, 1349–1357.
Candy, J. M., Morrison, C., Paton, R. D., et al. (1998). Salicylate toxicity masquerading as malignant hypertension, Paediatric Anaesthesia 8, 421–423.
Cannon, G., Caldwell, J., Holt, P., et al. (1998). MK-0966, a specific COX-2 inhibitor, for clinical efficacy comparable to Diclofenac in the treatment of knee and hip osteoarthritis (OA) in a 26 week controlled clinical trial, Arthitis Rheum. 41 (Suppl. 9), S83.
Cannon, G. W., Caldwell, J., Holt P., et al. (2000). Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip, Arthritis Rheum. 43, 978–987.
Capell, H. A., Rennie, J. A. N., Rooney, P. J., et al. (1979). Patient compliance: a novel method of testing nonsteroidal anti-inflammatory analgesics in rheumatoid arthritis, J. Rheumatol. 6, 584–593.
Care, G. R., Harfield, B. and Chamberlain, M. A. (1981). And have you done your exercises?, Physiotherapy. 67, 180.
Caron, J. P., Fernandes, J. C., Martel-Pelletier, J., et al. (1996). Chondroprotective effect of intraar-ticular injection of interleukin-1 receptro antagonist in experimental osteoarthritis: suppression of collagenase-1 expression, Arthritis Rheum. 39, 1535–1544.
Carr, A J. (1999). Beyond disability: measuring the social and personal consequences of osteoarthritis, Osteoarthritis Cartilage 7, 230–238.
Catella-Lawson, F., McAdam, B., Morrison, B. et al. (1999). Effects of specific inhibitor of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids, J. Pharm. Exper. Ther. 289, 735–741.
Chahade, W. H. and Josef, H. (1978). Clinical evaluation of the efficacy and tolerance of sulindac in patients with osteoarthritis of the hip and/ or knee during 144 weeks: Comparative study with aspirin during the first 96 weeks, Eur. J. Rheum. Inflam. 1, 41–44.
Chakraborty, I., Das, S. K., Wang, J., et al. (1996). Developmental expression of the cyclooxygenase-1 and cyclooxygenase-2genes in the peri-implantationmouse uterus and their differential regulation by the blastocyst and ovarian steroids, J. Mol. Endocrinol. 16, 107–122.
Chamberlain, M. A., Care, G. and Harfield, B. (1982). Physiotherapy in osteoarthritis of the knees. A controlled trial of hospital versus home exercises, Int. Rehab. Med. 4, 101–106.
Chan, T. Y. (1990). Potential dangers from topical preparations containing methylsalicylate, Human and Exper. Toxicol. 15, 747–750.
Chen, M. M. and Lee, C. S. (1985). Cimetidine–acetaminophen interaction in humans, J. Clin. Pharmacol. 25, 227–229.
Chrubasik, S., Eisenberg, E., Balan, E., et al. (2000). Treatment of low back pain exacerbations with willow bark extract: a randomized double-blind study, Am. J. Med. 109 (1), 9–14.
Cimmino, M. A., Cutolo, M., Samanta, E., et al. (1982). Short-term treatment of osteoarthritis: a comparison of sodium meclofenamate and ibuprofen, J. Int. Med. Res. 10, 46–52.
Clive, D. M. and Stoff, J. S. (1984). Renal syndromes associated with nonsteroidal anti-inflammatory drugs, New Engl. J. Med. 310, 563–572.
Cockcroft, D. W. and Gault, M. H. (1976). Prediction of creatinine clearance from serum creatinine, Nephron. 16, 31–41.
Cohen-Haguenauer, O. (1995). Overview of regulation of gene therapy in Europe: a current statement including reference to US regulation, Hum. Gene. Ther. 6, 773–785.
Cooper, D. E. and DeLee, J. C. (1994). Reflex sympathetic dystrophyof the knee, J. Am. Acad. Orthop. Surg. 2, 79–86.
Cooper, S. A. (1984). Five studies on ibuprofen for postsurgical dental pain, Am. J. Med. 77, 70–77.
Cooper, S. A., Schachtel, B. P., Goldman, E., et al. (1989). Ibuprofen and acetaminophen in the relief of acute pain: A randomised double-blind, placebo-controlled study, J. Clin. Pharmacol. 29, 1026–1030.
Co-Operating Clinics Committee. (1973). A controlled trial of gold salt therapy in rheumatoid arthritis, Arthritis Rheum. 16, 353–358.
Cornhill, J. and Rowley-Jones, D. (1984). Is sustained release ibuprofen as effective as piroxicam? A comparison in patients with osteoarthritis, Eur. J. Rheum. Inflam. 7, 114–121.
Creamer, P. (2000). Osteoarthritis pain and its treatment, Curr. Opin. Rheumatol. 12, 450–455.
Creamer, P. and Hochberg, M. C. (1997). Why does osteoarthritis of the knee hurt? —sometimes, Br. J. Rheumatol. 36, 726–728.
Creamer, P. and Hochberg, M. C. (1998). The relationship between psychological variables and pain reporting in osteoarthritis of knee, Arthritis Care Res. 11, 60–65.
Creamer, P., Hunt, M. and Dieppe, P. (1996). Pain mechanisms in osteoarthritis of the knee: effect of intra-articular anaesthetic, J. Rheumatol. 23, 1031–1036.
Creamer, P. and Lethbridge-Cejku, M. and Hochberg, M. C. (1998). Where does it hurt? Pain localization in osteoarthritis of the knee, Osteoarthritis Cartilage 6, 318–323.
Creamer, P., Lethbridge-Cejku, M., Costa, P., et al. (1999a). The relationship of anxiety and depression with self-reported knee pain in the community: Data from the Baltimore Longitudinal Study of Aging, Arthritis Care Res. 12, 3–7.
Creamer, P., Lethbridge-Cejku, M. and Hochberg, M. C. (1999b). Determinants of pain severity in knee osteoarthritis: effect of demographic and psychosocial variables using 3 pain measures, J. Rheumatol. 26, 1785–1792.
Crippen, J. S. (1993). Acetaminophen hepatotoxicity: Potentiation by isoniazid, Am. J. Gastroenterol. 88, 590–592.
Crofford, L. J. (1997). COX-1 and-2 tissue expression; implications and prediction, J. Rheumatol. 24 (Suppl. 49), 15–19.
Crofford, L. J., Wilder, R. L., Ristimaki, A. P., et al. (1994). Cyclooxygenase-1 and-2 expression in rheumatoid synovial tissues: effects of interleukin-1ß, phorphol ester, and corticosteroids, J. Clin. Invest. 93, 1095–1101.
Crome, P., Kimber, G. R., Wainscott, G., et al. (1981). The effect of the simultaneous administration of oral metoclopramide on the absorption of paracetamol in healthy volunteers, Br. J. Clin. Pharmacol. 11, 430–431P.
Crowther, R., Holbrook, A. M., Kenwright, R., et al. (1997). Drug interactions among commonly used medications. Chart simplifies data from critical literature review, Canad. Family Physician 43, 1972–1981.
Cryer, B. and Feldman, M. (1998). Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs, Am. J. Med. 104, 413–421.
Dahlberg, L., Lohmander, L. S. and Ryd, L. (1994). Intra articular injections of hyaluronanin patients with cartilage abnormalities and knee pain. A one year double-blind, placebo-controlled study, Arthritis Rheum. 37, 521–528.
Dart, R. C. and Kuffner, E. K. (2001). Use of acetaminophen in alcoholic patients: comment on the 2000 update of the American College of Rheumatology recommendations for management of hip and knee osteoarthritis, Arthritis Rheum. 44, 2449.
Davenport H. W. (1967). Salicylate damage to the gastric mucosal barrier, N. Engl. J. Med. 276, 1307–1312.
Davies, G. M., Watson, D. J. and Bellamy, N. (1999). Comparison of the responsiveness and relative effect size of the Western Ontario and McMaster Universities Osteoarthritis Index and the short-form Medical Outcomes Study Survey in a randomized clinical trial of osteoarthritis patients, Arthritis Care Res. 12, 172–179.
Davis, M. A., Ettinger, W. H., Neuhaus, J. M., et al. (1992). Correlates of knee pain among US adults with and without radiographic knee osteoarthritis, J. Rheumatol. 19, 1943–1949.
Day, R., Luza, A., Castenada, O., et al. (1999). Rofecoxib, a COX-2 specific inhibitor (C-251), had clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis (OA) in a 6-week controlled clinical trail, Ann. Rheum. Dis. (EULAR) p. 207, Abstract 860.
de Blécourt, J. J. (1975a). A comparative study of ibuprofen (Brufen) and indomethacin (Indocid) in uncomplicated gonarthrosis and coxarthrosis, Curr. Med. Res. and Opin. 3, 477–480.
de Blécourt, J. J. (1975b). A comparative study of ibuprofen (Brufen) and indomethacin (Indocid) in uncomplicated arthrosis, Nederlands tijdschrift voor Geneeskund, 119 (Suppl. 51), 2032–2034.
de Brum-Fernandez, A. J. (1997). New perspectives for non-steroidal anti-inflammatory therapy, J. Rheumatol. 24 (2), 246–248.
de Meijer, A. Vollard, H., de Metz, M., et al. (1999). Meloxicam, 15 mg/ day, spares platelet function in healthy volunteers, Clin. Pharmacol. Ther. 66, 425–430.
Deal, C. L. and Moskowitz, R. W. (1999). Nutraceuticals as therapeutic agents in osteoarthritis. The role of glucosamine, chondroitin sulfate, and collagen hydrolysate, Rheum. Clinics N. Amer. 25, 279–295.
Deal, C. L., Schnitzer, T. J., Lipstein, E., et al. (1991). Treatment of arthritis with topical capsaicin: a double-blind trial, Clin. Therapeutics 13, 383–395.
Deener, F. and Richardson, B. (2001). Review of gastrointestinal tolerability and safety of Meloxicam, Inflammopharm. 9, 71–80.
Degner, F. and Richardson, B. (2001). Review of gastrointestinaltolerability and safety of Meloxicam, Inflammopharmacology 9, 71–80.
Dequeker, J., Hawkey, C., Kahan, H., et al. (1998). Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis, Brit. J. Rheumatol. 37, 946–951.
Deyle, G. D., Henderson, N. E., Matekel, R. L., et al. (1999). Effectiveness of manual physical therapy and exercise of the knee, Am. Intern. Med. 132, 173–181.
Di Perri, T., Auteri, A., Caruso, I., et al. (1987b). Multi-center double-blind randomized clinical trial of imidazole salicylate versus ibuprofen in patients with osteoarthritis, Int. J. Clin. Pharm. Ther. Tox. 25, 479–482.
Diamond, H. S. (1976). Double-blind crossover study of fenoprofen and aspirin in osteoarthritis, J. Rheum. 3 (Suppl), 67–70.
Dick, C., Dick, P. H., Nuki, G., et al. (1969). Effects of anti-inflammatory drug therapy on clearance of 133 Xe from knee joints in patients with rheumatoid arthritis, Br. Med. J. 3, 278–280.
Dieppe, P. (1993). Management of osteoarthritis of the hip and knee joints, Curr. Opin. Rheumatol. 5, 487–493.
Dieppe, P. (2001). Concerns about the methodology used in developing the 2000 update of the Amer-ican College of Rheumatology recommendations for management of hip and knee osteoarthritis, Arthritis Rheum. 44, 2450–2451.
Dieppe, P. A. and Huskisson, E. C. (1978). Diflunisal and acetylsalicylic acid: a comparison of efficacy in osteoarthritis, of nephrotoxicity, and of anti-inflammatory activity in the rat, in: Diflunisal in Clinical Practice, Proceedings of a Conference at the XIVth International Congress of Rheumatology, San Francisco, K. Miehlke, (Ed.), pp. 57–61. Futura, New York.
Dieppe, P. and Huskinsson, E. (1979). Diflusinal and aspirin: a comparison of efficacy and nephrotoxicityin osteoarthritis, Rheumatol. Rehabil. 18, 53–56.
Dieppe, P. A., Sathapatayavongs, B., Jones, H. E., et al. (1980). Intra-articular steroids in osteoarthri-tis, Rheumatol. Rehab. 19, 212–217.
Dieppe, P., Cushnaghan, J., Jasani, M. K., et al. (1993a). A two year, placebo-controlled trial of non-steroidal anti-inflammatory therapy in osteoarthritis of the knee joint, B. J. Rheumatol. 32, 595–600.
Dieppe, P., Cushnaghan, J., Young, P., et al. (1993b). Prediction of the progression of joint space narrowing in osteoarthritis of the knee by bone scintigraphy, Ann. Rheum. Dis. 52, 557–563.
Dieppe, P. A., Franke., S. J. and Toth, B. (1993c). Is research into treatment of osteoarthritis with non-steroidal anti-inflammatory drugs misdirected?, Lancet 341, 353–354.
Dieppe, P., Basler, H. D., Chard, J., et al. (1999). Knee replacement surgery for osteoarthritis: effec-tiveness, practice variations, indications and possible determinants of utilization, Rheumatology 38, 73–83.
Dieppe, P., Cushnaghan, J., Tucker, M., et al. (2000). The Bristol OA 500 study: progression and impact of the disease after 8 years, Osteoarthritis Cartilage 8, 63–68.
DiPasquale, G. (1993). Pharmacologic control of cartilage degeneration in osteoarthritis, in: Joint Cartilage Degeneration: Basic and Clinical Aspects, J. F. Woessner, D. S. Howell (Eds), pp. 457–502. Marcel Dekker, New York.
Dixon, A. S., Jacoby, R. K. and Berry, H. (1988). Clinical trial of intra-articular injection of sodium hyaluronate in patients with osteoarthritis of the knee, Curr. Med. Res. Opin. 11, 205–213.
Doherty, M. and Jones, A. (1995). Indomethacin hastens large joint osteoarthritis in humans — how strong is the evidence?, J. Rheumatol. 22, 2013.
Dordoni, B., Willson, R. P. H., Thompson, R. P. H., et al. (1973). Reduced absorption of paracetamol by activated charcoal and cholestyramine: a possible therapeutic measure, Br. Med. J. 3, 86–87.
Downie, R. S. and Macnaughton, J. (2000). Clinical Judgement. Evidence in Practice. Oxford University Press, Oxford, England.
Doyle, D. V., Dieppe, P. A., Scott, J., et al. (1981). An articular index for the assessment of osteoarthritis, Ann. Rheum. Dis. 40, 75–78.
Dreiser, R. L. and Tisne-Camus, M. (1993). DHEP plasters as a topical treatment of knee OA — a double-blind placebo-controlled study, Drugs under Experimental and Clinical Research 19, 117–123.
Dunn, M. J. (1987). The role of arachidonic acid metabolites in renal homeostasis: nonsteroidal anti-infl ammatory drugs on renal function and biochemical, histological and clinical effects and drug interactions, Drugs 33 (Suppl. 1), 56–66.
Dunn, M. J. and Zambraski, E. J. (1980). Renal effects of drugs that inhibit prostaglandin synthesis, Kidney Int. 18, 609–622.
Easterbrook, P. J., Berlin, J. A., Gopalan, R., et al. (1991). Publicationbias in clinical research, Lancet 337, 867–872.
Eccles, M., Freemantle, N., Mason, J., et al.(1998). North of England Nonsteroidal Anti-inflammatory Drug Guideline Group. North of England Evidence-based Guideline Development Project: sum-mary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis, Brit. Med. J. 317, 526–530.
Editorial (1999). Osteoarthritis: time to shift to paradigm, Brit. Med. J. 318, 1299–1300.
Edwards, R. and Oliphant, J. (1992). Paracetamol toxicity in chronic alcohol abusers — a plea for greater consumer awareness, NZ Med. J. 105, 174–175.
Egger, M. and Davey-Smith, G. (1995). Misleading meta-analysis, Br. Med. J. 310, 752–754.
Ehrich, E., Schnitzer, T., Kivitz, A., et al. (1997). MK-966, a highly selective COX-2 inhibitor, was effective in the treatment of osteoarthritis (OA) of the knee, and hip in a 6-week placebo controlled study, Arth. Rheum. 40 (Suppl. 9), S85.
Ehrich, E., Bolognese, J., Kong, S., et al. (1998a). Improvement in SF 36 mental health domains with treatment of OA: result of decreased pain and disability or independent mechanisms, Arth. Rheum. 41 (Suppl. 9), 1134.
Ehrich, E., Schnitzer, T., Weaver, A., et al. (1998b). Treatment with MK-966 (Vioxx™), a specific COX-2 inhibitor, resulted in clinical improvement in osteoarthritis of the knee and hip that was sustained over six months, Rheum. in Europe 27 (Suppl. 2).
Ekstrom, P., Carling, L., Wetterhus, S., et al. (1996). Prevention of peptic ulcer and dyspeptic symptoms with omeprozole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study, Scand. J. Gastroenterol. 31, 753–758.
Elliott, S. L., Yeomand, N. D., Buchanan, R. R., (1994). Efficacy of 12 months misoprostol as prophylaxis against NSAID-induced gastric ulcers. A placebo-controlled trial, Scand. J. Rheumatol. 23, 171–176.
Emery, P. (1996). Pharmacology safety and therapeutics of COX-2 inhibitors, in: Improved Non-Steroidal Anti-Inflammatory Drugs, Vane, J., Botting, J. and Botting, R. (Eds), pp. 229–242. Kluwer, Dordrecht, The Netherlands.
Essigman, W. K., Chamberlain, M. A. and Wright, V. (1979). Diflunisal in osteoarthrosis of the hip and knee, Ann. Rheum. Dis. 38, 148–151.
Ettinger, W. H. J. and Afable, R. F. (1994). Physical disability from knee osteoarthritis: the role of exercise as an intervention, Med. Sci. in Sports and Exercise 26, 1435–1440.
Ettinger, W. H. Jr., Burns, R., Messier, S. P., et al. (1997). A randomized trial comparing aerobic exercise and resistance exercise with a health education program in older adults with knee osteoarthritis. The Fitness Arthritis and Seniors Trial (FAST), J. Am. Med. Assoc. 277, 25–31.
European Drug Guidelines. (1985). Guidelines for the Clinical Investigators of Drugs used in Rheumatic Diseases. European Drug Guidelines, Series 5. World Health Organization. Regional Office for Europe, Copenhagen. European League against Rheumatism. March, pp. 21–24.
Evans, C. H. and Robbins, P. D. (1994). Gene therapy for arthritis, in: Gene Therapeutics: Methods and applications of direct gene transfer, Wolff, J. A. (Ed.), pp. 320–324. Birkhauser, Boston.
F.D.A. Guidelines (1988). Guidelines for the Clinical Evaluation of Anti-rheumatic Drugs (Adult and Children). U.S. Department of Health and Human Services. Public Health Services. Food and Drug Administration, April, 115.
Felson, D. T. (2001). The verdict favors nonsteroidal antiinflammatory drugs for treatment of osteoarthritis and a plea for more evidence on other treatments, Arthritis Rheum. 44, 1477–1480.
Felson, D. T., Zhang, Y., Hannan, M. T., et al. (1997). Risk factors for incident radiographic knee osteoarthritis in the elderly: the FraminghamStudy, Arthritis Rheum. 40, 728–733.
Fernandes, J., Tardif, G., Martel-Pelletier, J., et al. (1999). In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints. Prevention of osteoarthritis progression, Am. J. Pathol. 154, 1159–1169.
Fernandes, J. C., Martel-Pelletier, J. and Pelletier, J. P. (2000). Gene therapy for osteoarthritis — new perspectives for the twenty-first century, Clin. Orthop. Rel. Res. 379 (Suppl.), 262–272.
Ferreira, S. H. (1980). Peripheral analgesia: mechanism of the analgesic action of aspirin like drugs and opiate-antagonists, Br. J. Clin. Pharmacol. 10, 237S–245S.
Fisher, C. A., Curtis, S. P., Resnick, H., et al. (2001). Treatment with etoricoxib, a cox-2 selective inhibitor, resulted in clinical improvement in knee and hip osteoarthritis (OA) over 52 weeks, Arthitis Rheum. 44 (Suppl. 9), abstract 495, S135.
Fisher, N. M., Pendergast, D. R., Gresham, G. E., et al. (1991). Muscle rehabilitation: its effect on muscular and functional performance of patients with knee osteoarthritis, Arch. Phys. Med. Rehabil. 72, 367–374.
Fisher, N. M., Gresham, G. E., Abrams, M., et al. (1993). Quantitative effects of physical therapy on muscular and functional performance in subjects with osteoarthritis of the knees, Arch. Phys. Med. Rehabil. 74, 840–847.
Fitzmaurice, D. A. and Murray, J. A. (1997). Potentiationof anticoagulant effect of warfarin, Postgrad. Med. J. 73, 439–440.
Floren, C.-H., Thesleff, P. and Milsson, A. (1987). Severe liver damage caused by therapeutic doses of acetaminophen, Acta. Med. Scand. 222, 285–288.
Foldes, K., Brandt, P., Gaal, M., et al. (1992). Nocturnal pain correlates with effusions in diseased hips, J. Rheumatol. 19, 1756–1758.
Forrest J. B. (1992). Sympathetic mechanisms of acute pain, Can. J. Anaesth. 39, 523–527.
Forrest J. B. (1998). Pathophysiology of acute pain, in: Acute Pain: Pathophysiology and Treatment, Forrest, J. (Ed.), pp. 31–65. Manticore, Grimsby Ontario, Canada.
Fortin, P. R., Clarke, A. E., Joseph, L., et al. (1999). Outcomes of total hip and knee replacement: preoperative functional status predicts outcomes at six months after surgery, Arthritis Rheum. 42, 1722–1728.
Fox P. L., Raina P. and Jadad A. R. (1999). Prevalence and treatment of pain in older adults in nursing homes and other long-termcare institutions: a systematic review, Can. Med. J. 160, 329–333.
Fremont-Smith, P. and Bayles, T. B. (1965). Salicylate therapy in rheumatoid arthritis, JAMA 192, 113–116.
Friedman, D. M. and Moore, M. E. (1980). The efficacy of intra articular steroids in osteoarthritis: a double-blind study, J. Rheumatol. 7, 850–856.
Fries, J. F., Spitz, P., Kraines, G. R., et al. (1980). Measurement of patient outcome in arthritis, Arthritis Rheum. 23, 137–145.
Fries, J. F., Williams, C. A. and Bloch D. A. (1991). The relative toxicity of nonsteroidal antiinflam-matory drugs, Arthritis Rheum. 34, 1353–1360.
Fröhlich, J. C. (1995). Prostaglandin ecdoperoxidase synthetase isoenzymes. The clinical relevance of selective inhibition, Ann. Rheum. Dis. 54, 942–943.
Gaffney, K., Ledingham, J. and Perry, J. D. (1995). Intra-articulartriamcinolone hexacetonide in knee osteoarthritis: factors influencing the clinical response, Ann. Rheum. Dis. 54, 379–381.
Garcia-Rodriguez, L. A., Cattaruzzi, C., et al. (1998). Risk of hospitalizationfor upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs, Arch. Intern. Med. 158, 33–39.
Garcia-Rodriguez, L. A. and Hernadez-Diaz S. (2001). Relative risk of upper gastrointestinal compli-cations among users of acetaminophen and non-steroidal anti-inflammatory drugs, Epidemiol. 12, 570–576.
Gerecz-Simon, E. and Kean, W. F. (1999a). Methods for application of topical nonsteroidal anti-infl ammatory drugs (TNSAIDs) in clinical trials, Inflammopharmacology 7, 329.
Gerecz-Simon, E. and Kean, W. F. (1999b). Efficacy and safety of topical nonsteroidal anti-inflammatory drugs (TNSAIDs) in musculoskeletal disorders, Inflammopharmacology 7, 330–331.
Ghosh, P. (1988). Anti-rheumatic drugs and cartilage, Baillière's Clin. Rheumatol. 2, 309–338.
Ghosh, P., Wells, C., Smith, M., et al. (1990). Chondroprotection, myth or reality: an experimental approach, Semin. Arthritis Rheum. 19 (Suppl. 1), 3–9.
Gibb, W. and Sun, M. (1996). Localization of prostaglandin H synthase type 2 protein and mRNA in term human fetal membranes and decidua, J. Endocrinol. 150, 497–503.
Glorioso, S., Todesco, S., Mazzi, A., et al. (1985). Double-blind multicentre study of the activity of S-adenosylmethioninein hip and knee osteoarthritis, Int. J. Clin. Pharm. Res. 5, 39–49.
Goodman, M. J., Kent, P. W. and Truelove, S. C. (1986). Inhibition of glucosamine synthesis by salicylates hydrocortisone and two non-ulcerogenic drugs, Arch. Int. Pharmacodyn. Ther. 226, 4–10.
Gould, G. S. (1996). Death and horses: two cases for the primacy of variation, in: Full House, The Spread of Excellence from Plato to Darwin, pp. 43–73. Harmony Books, New York.
Grace, D., Rogers. J., Skeith, K., et al. (1999). Topical diclofenac versus placebo: a double blind randomized clinical trial in patients with osteoarthritis of the knee, J. Rheumatol. 26, 2659–2683.
Graham, D. Y. and Smith, J. L. (1985). Effects of aspirin and an aspirin–acetaminophen combination on the gastric mucosa of normal subjects, Gastroenterology 88, 1922–1925.
Graham, D. Y., White, R. H., Moreland, L. W., et al. (1993). Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs, Ann. Intern. Med. 119, 257–262.
Graham G. G., Day R. O., Milligan M. K., et al. (1999). Current concepts of the actions of paracetamol (acetaminophen) and NSAIDs, Inflammopharmacology 7, 255–263.
Grayson, M. F. (1978a). Two trials of diflunisal in osteoarthritis, Curr. Med. Res. Opin. 5, 567–571.
Grayson, M. F. (1978b). A clinical trial of diflunisal against aspirin in osteoarthritis, Rheum. Rehab. 17, 265–269.
Grecomoro, G., Martorana, U. and DiMarco, C. (1987). Intra-articular treatment with sodium hyaluronate in gonarthrosis: a controlled clinical trial versus placebo, Pharmatherapeutica 5, 137–141.
Greenberg, H. E., Gottesdiener, K., Huntington, M., et al. (2000). A new cyclooxygenase-2inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers, J. Clin. Pharmacol. 40 (12 Pt 2), 1509–1515.
Griffin, M. R., Brandt, K. D., Liang, M. H., et al. (1995). Practical management of osteoarthritis. Integration of pharmacological and nonpharmacologic measures, Arch. Fam. Med. 4, 1049–1055.
Griswald, D. E. and Adams, J. L. (1996). Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): rationale for selective inhibition and progress to date, Med. Res. Rev. 16 (2), 181–206.
Guan, Y., Chang, M., Cho, W., et al. (1997). Cloning, expression, and regulation of rabbit cyclooxygenase-2 in renal medullary interstitial cells, Am. J. Physiol. 273, F18–F26.
Guidelines for the diagnosis, investigation and management of osteoarthritis of the hip and knee. Report of a joint working group of the British Society for Rheumatology and the Research Unit of the Royal College of Physicians. (1993). J. Roy. Coll. Physicians Lond. 27, 391–396.
Hardin, J. G. and Kirk, K. A. (1979). Comparative effectiveness of five analgesics for the pain of rheumatoid arthritis, J. Rheumatol. 6, 405–442.
Harper, S., Lee, M., Curtis, S., et al. (2001). A lower incidence of upper-GI perforations, ulcers and bleeds (PUBs) in patients treated with etoricoxib vs. nonselective cyclooxygenase inhibitors (NSAIDs), Arthritis Rheum. 44, abstract 1590, S318.
Harris, R. C., McKanna, J., Akai, Y., et al. (1994). Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction, J. Clin. Invest. 94, 2504–2510.
Hart, D. J., Doyle, D. V. and Spector, T. D. (1999). Incidence and risk factors for radiographic knee osteoarthritis in middle-aged women: the Chingford Study, Arthritis Rheum. 42, 17–24.
Hart, F. D. (1987). Rational use of analgesics in the treatment of rheumatic disorders, Drugs 33, 85–93.
Hawker, G., Wright, J., Coyle, P., et al. (1998). Health-related quality of life after knee replacement, J. Bone. Jt. Surg. 80A, 163–173.
Hawkey, C. J. (1999). COX-2 inhibitors, Lancet 353, 307–314.
Hawkey, C. J., Kahan, A., Steinbruck, K., et al. (1998a). Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxi-cam Large-scale International Study Safety Assessment, Brit. J. Rheumatol. 37, 937–945.
Hawkey, C. J., Karrasch, J. A. and Szczepanski, L. (1998b). Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs, New Engl. J. Med. 338, 727–734.
Hawkey, C., Laine, L., Mortensen, E., et al. (1999). Treatment of osteoarthritis with rofecoxib, a cyclooxygenase-2 (COX-2) specific inhibitor, was associated with a lower incidence of gas-troduodenal ulcers compared to ibuprofen and was comparable to placebo treatment, Ann. Rheum. Dis. (EULAR) p. 207, Abstract 861.
Henderson, E. B., Smith, E. C., Pegley, F., et al. (1994). Intra-articular injection of a 750 kD. hyaluronan in the treatment of osteoarthritis: a randomized single center double-blind placebo-controlled trial of 91 patients demonstrating lack of efficacy, Ann. Intern. Med. 53, 529–534.
Henry, D., Lim, L. L., Garcia Rodriguez, L. A., et al. (1996). Variability in risk of gastrointestinal complications with individual nonsteroidal anti-inflammatory drugs: results of a collaborative meta-analysis, Brit. Med. J. 312, 1563–1566.
Herman, J. H., Appel, A. M. and Hess, E. V. (1987). Modulation of cartilage destruction by select non-steroidal anti-inflammatory drugs, Arthritis Rheum. 30, 257–265.
Higgs, G. A. (1980). Arachidonic acid metabolism, pain and hyperalgesia: the mode of action of non-steroid analgesics, Br. J. Clin. Pharmacol. 10, 233S–235S.
Highton, J. and Grahame, R. (1980). Benoxaprofenin the treatment of osteoarthritisq—A comparison with ibuprofen, J. Rheum. 7 (Suppl.), 125–131.
Hingorani, K. (1976). A comparative study of azapropazone and ibuprofen in the treatment of osteoarthritis of the knee, Curr. Med. Res. Opin. 4, 57–64.
Hla, T. and Neilson, K. (1992). Human cyclooxygenase-2 DNA, Proc. Natl. Acad. Sci. USA 89, 7384–7388.
Hochberg, M. C., Altman, R. D., Brandt, K. D., et al. (1995a). Guidelines for the medical management of osteoarthritis. Part I Osteoarthritis of the hip. American College of Rheumatology, Arthritis Rheum. 38, 1535–1540.
Hochberg, M. C., Altman, R. D., Brandt, K. D., et al. (1995b). Guidelines for the medical management of osteoarthritis. Part II Osteoarthritis of the knee. American College of Rheumatology, Arthritis Rheum. 38, 1541–1546.
Hochberg, M. C., Altman, R. D., Brandt, K. D., et al. (1997). Design and conduct of clinical trials in osteoarthritis. Preliminary recommendations from a task force of the Osteoarthritis Research Society, J. Rheumatol. 24, 792–794.
Hodler, J., Trudell, D., Pathria, M. N., et al. (1992). Width of the articular cartilage of the hip: quantification by using fat-suppression spin-echo MR imaging in cadavers, Am. J. Roentgenol. 159, 351–355.
Hosie, J., Distel, M. and Bluhmki, E. (1997). Efficacy and tolerabilityof meloxicamversus piroxicam in patients with osteoarthritis of the hip and knee, Clin. Drug Invest. 13, 175–184.
Hubbard, R., Geis, G. S., Woods, E., et al. (1998). Efficacy, tolerability, and safety of Celecoxib, a specific COX-2 inhibitor in osteoarthritis, Arthritis Rheum. 41 (Suppl. 9), S196. Abstract 982.
Hui, X., Hewitt, P. G., Poblete, N., et al. (1998). In vivo bioavailability and metabolism of topical diclofenac lotion in human volunteers, Pharm. Res. 15 (10), 1589–1595.
Hungin, A. P. S. and Kean W. F. (2001). Nonsteroidal anti-inflammatory drugs: overused or underused in osteoarthritis?, Amer. J. Med. 110, 8s–11s.
Hurley, M. V. and Scott, D. L. (1998). Improvements in quadriceps sensorimotor function and disability of patients with knee osteoarthritis following a clinically practicable exercise regime, Br. J. Rheumatol. 37, 1181–1187.
Huskisson, E. C. (1974). Simple analgesics for arthritis, Br. Med. J. 4, 196–200.
Huskisson, E. C. and Donnelly, S. (1999). Hyaluronic acid in the treatment of osteoarthritis of the knee, Rheumatology 38, 602–607.
Huskisson, E. C. and Scott, J. (1976). How double-blind is double-blind? And does it matter, Br. J. Clin. Pharmacol. 3, 331–332.
Huskisson, E. C. and Scott, J. (1978). Sulindac. Trials of a new anti-inflammatory drug, Ann. Rheum. Dis. 37, 89–92.
Huskisson, E. C., Berry, P. G., Gishen, P., et al. (1995). Effects of anti-inflammatory drugs on the progression of osteoarthritis of the knee. LINK Study Group. Longitudinal investigation of nonsteroidal anti inflammatory drugs in knee osteoarthritis, J. Rheumatol. 22, 1941–1946.
Hyleh, E. M., Heiman, H., Skates, S. J., et al. (1998). Acetaminophen and other risk factors for excessive warfarin anticoagulants, J. Amer. Med. Assoc. 279, 702–703.
IMS Health (1999). www.ims-global.com/insight/news_story/news_story_000330a.htm— 15k
IMS Health, Canada (1999). www.imshealthcanada.com/htmen/4_2_1_14.htm — 15k
Ivey, K. J. (1986). Gastrointestinal intolerance and bleeding with non-narcotic analgesics, Drugs 32 (Suppl. 4), 71–79.
Jamison, R. N., Anderson, K. O., Peeters-Asdourian, C., et al. (1994). Survey of opioid use in chronic nonmalignant pain patients, Reg. Anesth. 19, 225.
Jankovic, D. and Wells, C. (2001). Regional Nerve Blocks. Blackwell Science, Berlin.
Jeal, W. and Benfield, P. (1997). Transdermal fentanyl: a review of its pharmacological properties and therapeutic efficacy in pain control, Drugs 53, 109–138.
Jobanputra, P. and Nuki, G. (1994). Nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis, Curr. Opin. Rheumatol. 6, 433–439.
Johnson, E. E. and Urist, M. R. (1998). One stage lengthening of femoral nonunion augmented with human bone morphogenetic protein, Clin. Orthop. 347, 105–116.
Johnson, E. E. and Urist, M. R. (2000). Human bone morphogenetic protein allografting for reconstruction of femoral nonunion, Clin. Orthop. 371, 61–74.
Johnson, E.E, Urist, M. R. and Finerman, G. A. (1992). Resistant nonunions and partial or complete segmental defects in long bones. Treatment with implants of a composite of human bone morphogenetic protein (BMP) and autolyzed, antigen extracted, allogenic (AAA) bone, Clin. Orthop. 277, 229–237.
Jones, D. A., Carleton, D. P., McIntyre, T. M., et al. (1993). Molecular cloning of human prostaglandin endoperoxide synthase type II, and demonstration of expression in response to cytokines, J. Biol. Chem. 268, 9049–9054.
Joubert, P. H., Kushlick, A. R., McNeill, W. G., et al. (1974). South African multicentre trial with Voltaren in osteo-arthritis of the knee, S. African Med. J. 48, 1973–1978.
Jouzeau, J. Y., Terlain, B., Abid, A., et al. (1997). Cyclooxygenase isoenzymes: how recent findings affect thinking about non-steroidal anti-inflammatory drugs, Drugs 53 (4), 563–582.
Juni, P., Rutjes, A. W. and Dieppe, P. A. (2002). Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?, BMJ 324, 1287–1288.
Kamali, F. (1993). The effect of probencid on paracetamol metabolism and pharmacokinetics, Eur. J. Clin. Pharmacol. 45, 551–553.
Kamali, F., Fry, J. R., Smart, H. L., et al. (1985). A double-blind placebo-controlledstudy to examine effects of sulcrafate on paracetamol absorption, Br. J. Clin. Pharmacol. 19, 113–114.
Kang, R., Ghivizzani, S. C., Muzzonigro, T. S., et al. (2000). Orthopaedic applications of gene therapy — from concept to clinic, Clin. Orthop. Rel. Res. 375, 324–337.
Kantor, T. G. (1980). Analgesics for arthritis, Clin. Rheum. 6, 525–531.
Kaps, C., Bramlage, C., Smolian, H., et al. (2002). Bone morphogenetic proteins promote cartilage differentiation and protect engineered artificial cartilage from fibroblast invasion and destruction, Arthritis Rheum. 46, 149–162.
Kean, W. F. and Buchanan, W. W. (1987). Variables affecting the absorption of non-steroidal anti-infl ammatory drugs from the gastrointestinal tract, Japan J. Rheumatol. 1(3), 159–170.
Kean, W. F., Lock, C. J. L., Rischke, J., et al. (1989). Effect of R and S enantiomers of naproxen on aggregation and thromboxane production in human platelets, J. Pharm. Sci. 78, 324–327.
Kean, W. F., Buchanan, W. W. and Rainsford, K. D. (1999). Therapeutics of ibuprofen in rheu-matic and other chronic and painful diseases, in: Ibuprofen. A Critical Bibliographic Review, K. D. Rainsford (Ed.), Chapter 6, pp. 277–353. Taylor and Francis, London.
Keating, E. M., Faris, P. M., Ritter, M. A., et al. (1993). Use of lateral heel and sole wedges in the treatment of medial osteoarthritis of the knee, Orthopaedic Rev. 22, 921–924.
Kessler, D. A., Siegel, J. P., Noguchi, P. D., et al. (1993). Regulation of somatic-cell therapy and gene therapy by the food and drug administration, N. Engl. J. Med. 329, 1169–1173.
Kidd B. L., Cruwys S., Mapp P. I., et al. (1992). Role of the sympathetic nervous system in chronic joint pain and inflammation, Ann. Rheum. Dis. 51, 1188–1191.
Kivitz, A., Eisen, G., Zhao, W. W., et al. (2001). The cox-2 specific inhibitor valdecoxib is as effective as the conventional NSAID naproxen in treating symptomatic osteoarthritis of the knee and demonstrates reduced gastrointestinal ulceration, Arthritis Rheum. 44 (Suppl. 9), abstract 500, S136.
Klein, B. (1982). Carpofen in osteoarthritis, Europ. J. Rheum. Inflame. 5, 507–513.
Knowles, S., Shapiro, L. and Shear, N. H. (2001). Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of 'sulfa' allergy, Drug Safiety 24(4), 239–247.
Koch, M., Dezi, A., Ferraris F., et al. (1996). Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosa injury. A meta-analysis of randomized controlled clinical trials, Arch. Int. Med. 156, 2321–2332.
Komhoff, M., Groen, H. J., Klein, T., et al. (1997). Localization of cyclooxygenase-1 and-2 in adult and foetal human kidney: implication for renal function, Am. J. Physiol. 272, F460–F468.
Komistek, R. D., Dennis, D. A., Northcut, E. J., et al. (1999). An in vivo analysis of the effectiveness of the osteoarthritic knee brace during heel-strike of gait, J. Arthroplasty 14, 738–742.
Konttinen, Y. T., Kemppinen, P., Segerberg, M., et al. (1994). Peripheral and neural mechanisms in arthritis, with particular reference to treatment of inflammation and pain, Arthritis Rheum. 37, 965–982.
Konturek, S. J., Piastucki, I., Brzozowski, T., et al. (1981). Role of prostaglandin in the formation of aspirin-induced ulcers, Gastrointerology 80, 4–9.
Kosinski, M., Kujawski, S. C., Martin, R., et al. (2002). Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response, Am. J. Manag. Care. 8, 231–240.
Kovar, P. A., Allegrante, J. P., MacKenzie, C. R., et al. (1992). Supervised fitness training in patients with osteoarthritis of the knee: a randomized, controlled trial, Ann. Intern. Med. 116, 529–534.
Kurumbail, R. G., Stevens, A. M., Gierse, et al. (1996). Structural basis for selective inhibition of cyclooxygenase by anti-inflammatory agents, Nature 384, 644–648.
Kwan, D. and Bartle, W. R. (1993). Drug interactions with warfarin, Med. J. Aust. 158, 574–575.
Laine, L., Harper, S., Simon, T., et al. (1999). For the Rofecoxib Osteoarthritis Endoscopy Study Group. A randomized trila comparing the effect of rofecoxib, a cyclooxygenase 2 specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis, Gastroenterology 117, 776–783.
Lambert, J. R., Cardon, N., Simpson, N. R., et al. (1985). A controlled comparison of tiaprofenic acid and ibuprofen in osteoarthritis, Int. J. Clin. Pharm. Res. 5, 161–164.
Langley, G. B. and Sheppard, H. (1984). Problems associated with pain measurement in arthritis; comparison of visual analogue and verbal rating scales, Clin. Exp. Rheumatol. 2, 231–234.
Langman, M., Jensen, D. and Watson, D. J. (1999a). Lower incidence of clinically evident upper GI perforation, ulcers, and bleeds in patients treated with rofecoxib versus non-specific cyclooxyge-nase inhibitors, Ann. Rheum. Dis. (EULAR) p. 207, Abstract 862.
Langman, M. J., Jensen, D. M., Watson, D. J., et al. (1999b). Adverse upper gastrointestinal effects of rofecoxib with NSAIDs, J. Am. Med. Assoc. 282, 1929–1933.
Ledingham, J., Dawson, S., Preslon, B., et al. (1993a). Radiographic progression of hospital referred osteoarthritis of the hip, Ann. Rheum. Dis. 52, 263–267.
Ledingham, J., Regan, M., Jones, A., et al. (1993b). Radiographic patterns and associations of osteoarthritis of the knee in patients referred to hospital, Ann. Rheum. Dis. 52, 520–526.
Ledley, F. D. (1994). Therapeutic promise of molecular genetics, J. Invest. Dermatol. 103 (5 Suppl.), 2S–5S.
Lee, P., Anderson, J. A., Miller, J., et al. (1976). Evaluation of analgesic action and efficacy of antirheumatic drugs. Study of 10 drugs in 684 patients with rheumatoid arthritis, J. Rheumatol. 3, 283–295.
Lequesne, M. G. (1987). The algofunctional indices for hip and knee osteoarthritis, J. Rheumatol. 24, 779–781.
Lequesne, M. G., Mery, C., Samson, M., et al. (1987). Indexes of severity for osteoarthritis of the hip and knee, Scan. J. Rheumatol. 65 (Suppl), 85–89.
Lequesne, M., Brandt, K., Bellamy, N., et al. (1994). Guidelines for testing slow-acting and disease-modifying drugs in osteoarthritis, J. Rheumatol. 21 (Suppl. 41), 65–71.
Lipsky, L. P. E., Abramson, S., Crofford, L., et al. (1998). The classification of cyclooxygenase inhibitors, J. Rheumatol. 25, 2298–2303.
Lloyd-Roberts, G. C. (1953). The role of capsular changes in osteoarthritis of the hip joint, J. Bone Jt. Surg. 35B, 627–642.
Lohmander, L. S. (1994). Articular cartilage and osteoarthritis: the role of molecular markers to monitor breakdown, repair and disease, J. Anat. 184, 477–492.
Lohmander, L. S. and Felson, D. T. (1997). Defining the role of molecular markers to monitor disease, intervention, and cartilage breakdown in osteoarthritis, J. Rheumatol. 24, 782–785.
Lorig, K., Lubeck, D., Kraines, R. G., et al. (1985). Outcomes of self-help education for patients with arthritis, Arthritis Rheum. 28, 680–685.
Lorig, K. R., Mazonson, P. D. and Holman, H. R. (1993). Evidence suggesting that health education for self-management in patients with chronic arthritis has sustained health benefits while reducing health care costs, Arthritis Rheum. 36, 439–446.
Lotz, M. (1999). The role of nitric oxide in articular cartilage damage, Rheum. Dis. Clinics N. Amer. 25, 269–282.
Luggen, M. E., Gartside, P. S. and Hess, E. V. (1989). Nonsteroidal anti-inflammatory drugs in rheumatoid arthritis: duration of use as a measure of relative value, J. Rheumatol. 16, 1565–1569.
Lund, B., Distel, N. and Bluhmki, E. (1998). A double-blind randomized, placebo-controlledstudy of efficacy and tolerance of meloxicamtreatment in patients with osteoarthritis of the knee, Scand. J. Rheum. 27, 32–37.
Luong, C., Miller, A., Barnett, J., et al. (1996). Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2, Nature Sctrct. Biol. 3, 927–933.
Lynch, J. M. and Fox, T. M. (2001). Use of acetaminophen in the treatment of osteoarthritis in patients with liver disease: comment on the 2000 update of the American College of Rheumatology recommendationsfor management of hip and knee osteoarthritis, Arthritis Rheum. 44, 2448–2449.
Makarowski, W., Zhao, W. W., Bevirt, T., et al. (2001). The COX-2 specific inhibitor valdecoxib is effective in treating symptomatic osteoarthritis of the hip, Arthritis Rheum. 44 (Suppl. 9), abstract 492, S134.
Manchester General Practitioner Group (1984). A study of naproxen and ibuprofen in patients with osteoarthritis seen in general practice, Curr. Med. Res. Opin. 9, 41–46.
March, L. (1997). Osteoarthritis, Med. J. Aust. 166, 98–103.
March, L., Irwig, L., Schwarz, J. et al. (1994). n of 1 trials comparing a non-steroidal anti-infl ammatory drug with paracetamol in osteoarthritis, Br. Med. J. 309, 1041–1045.
Marks, R. (1994). Reliability and validity of self-paced walking time measures for knee osteoarthritis, Arthritis Care Res. 7, 50–53.
Marsepiol, T., Mahassani, B., Roudiak, N., et al. (1989). Potentialisation de la toxicity hépatique et rénale du paracétamol par le phénnobarbital, JEUR 2, 118–120.
Martin, R. M., Biswas, P. and Mann, R. D. (2000). The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19,087 patients in general practice in England: cohort study, Br. J. Clin. Pharmacol. 50, 35–42.
Martinez, L. M., Homan, K. I., Smyth, C. J., et al. (1980). A comparison of naproxen, indomethacin and aspirin in osteoarthritis, J. Rheum. 7, 711–716.
Masferrer, J. L., Zweipel, B. S., Seibert, K., et al. (1990). Selective regulations of cellular cyclooxy-genase by dexamethasone and endotoxin in mice, J. Clin. Invest. 86, 1375–1379.
Mather, L. E., Tucker, G. T., Pflug, A. E., et al. (1975). Meperidine kinetics in man, Clin. Pharmacol. Ther. 17, 21–31.
Maulding, T. S., Redeker, A. C. and Kanel, G. C. (1989). Twenty isoniazid-associateddeaths in one state, Am. Rev. Respir. Dis. 140, 700–705.
Maulding, T. S., Redeker, A. G. and Kanel, G. C. (1991). Acetaminophen, isoniazid, and hepatic toxicity, Ann. Intern. Med. 114, 431.
Maurer, B. T., Stern, A. G., Kinossian, B., et al. (1999). Osteoarthritis of the knee: isokinetic quadriceps exercise versus an educational intervention, Arch. Phys. Med. Rehab. 80, 1293–1299.
Max, M. B., Schafer, S. C., Culnane, M., et al. (1988). Associationof pain relief with drug side-effects in post hepatic neuralgia, Clin. Pharmacol. Ther. 43, 363–371.
Mazzuca, S. A., Brandt, K. D., Katz., B. P., et al. (1993). Therapeutic strategies distinguish com-monly based primary care physicians from rheumatologists in the management of osteoarthritis, J. Rheumatol. 20, 80–86.
Mazzuca, S. A., Brandt, K. D. and Katz, B. P. (1997a). Is conventional radiography suitable for evaluation of a disease-modifying drug in patients with knee osteoarthritis?, Osteoarthritis Cartilage 5, 217–226.
Mazzuca, S. A., Brandt., K. D. and Katz, B. P. (1997b). Effects of self-care education on the health status of inner-city patients with osteoarthritis of the knee, Arthritis Rheum. 40, 1466–1474.
Mazzuca, S. A. and Brandt, K. D. (1999). Plain radiography as a outcome measure in clinical trials involving patients with knee osteoarthritis, Rheum. Dis. Clin. N. Am. 54, 467–480.
Mazzuca, S. A., Brandt, K. D., Katz, B. P., et al. (1999). Reduced utilization and cost of primary care clinic visits resulting form self-care education for patients with osteoarthritis of the knee, Arthritis Rheum. 42, 1267–1273.
McAlindon, T. and Dieppe, P. (1990). The medical management of osteoarthritis of the knee: an inflammatory issue?, Br. J. Rheumatol. 29, 471–473.
McAlindon, T. E., LaValley, M. P., Gulin, J. P., et al. (2000). Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis, J. Amer. Med. Assoc. 283, 1469–1475.
McCarthy, G. M. and McCarty, D. J. (1992). Effect of topical capsaicin in the therapy of painful osteoarthritis of the hands, J. Rheumatol. 19, 604–617.
McClain, C. J., Kromhout, J. P. and Peterson, F. J. (1980). Potentiation of acetaminophen hepatotoxi-city by alcohol, JAMA 244, 251–253.
McDermott, F. T. (1985). Mortality from bleeding peptic ulcer. Alfred Hospital Melbourne, 1976–1980, Med. J. Aust. 142, 11–14.
McMahon, F. G., Jain, A. and Orel, A. (1976). Controlled evaluationof fenoprofenin geriatric patients with osteoarthritis, J. Rheum. 3 (Suppl.), 76–82.
McPherson, K., Britton, A. R. and Wenneberg, J. E. (1997). Are randomized controlled trials controlled? Patient preferences and unblind trials, J. Roy. Soc. Med. 90, 652–656.
McQuay, H. and Moore, A. (1999a). Topically applied non-steroidal anti-inflammatory drugs, in: An Evidenced-based Resource for Pain Relief, pp. 102–117. Oxford University Press, Oxford, UK.
McQuay, H. and Moore, A. (1999b). An Evidenced Based Resource for Pain Relief, pp. 58–77, 138–146. Oxford University Press, Oxford, UK.
Meenan, R. F., Gertmann, P. N. and Mason, H. (1980). Measuring health status in arthritis: the Arthritis Impact Measurement Scales, Arthritis Rheum. 23, 146–152.
Melander, O., Lidén, A. and Melander, A. (1995). Pharmacokinetic interaction of alcohol and acetylsalicylic acid, Eur. J. Clin. Pharmacol. 48, 151–153.
Melton, J. W. 3rd, Lussier, A., Ward, J. R., et al. (1978). Naproxen vs. aspirin in osteoarthritis of the hip and knee, J. Rheum. 5, 338–346.
Mengle-Law, L., Hubbard, R. C., Karim, A., et al. (1997). A study of the platelet effects of SC-58635, a novel COX-2-selective inhibitor, Arthritis Rheum. 40 (Suppl. 9), 593.
Michalets, E. L. (1998). Update: Clinically significant cytochrome P450 drug interactions, Pharma-cotherapy 18, 84–112.
Mills, S. Y., Jacoby, R. K., Chacksfield, M., et al. (1996). Effect of a proprietary herbal medicine on the relief of chronic arthritic pain: a double-blind study, Br. J. Rheumatol. 35 (9), 874–878.
Miners, J. O., Attwood, J. and Birkett, D. J. (1983). Influence of sex and oral contraceptive steroids on paracetamol metabolism, Br. J. Clin. Pharmacol. 16, 503–509.
Miners, J. O., Attwood, J. and Birkett, D. J. (1984). Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways, Clin. Pharmacol. Ther. 35, 480–486.
Minor, M. A. (1994). Exercise in the management of osteoarthritis of the knee and hip, Arthritis Care and Research. 7, 198–204.
Minor, M. A. (1999). Exercise in the treatment of osteoarthritis, Rheum. Dis. Clinics North Amer. 25, 397–415.
Mitchell, M. C., Hanew, T., Meredith, C. G., et al. (1983). Effects of oral contraceptive steroids on acetaminophen metabolism and elimination, Clin. Pharmacol. Ther. 34, 48–53.
Moore, R. A., Tramer, M., Carroll, D., et al. (1998). Quantitative systematic review of topically applied nonsteroidal anti-inflammatory drugs, Br. Med. J. 316, 333–338.
Moulding, T. S., Redeker, A. G. and Kanel, G. C. (1989). Twenty isoniazid-associateddeaths in one state, Am. Rev. Respir. Dis. 140, 700–705.
Moulding, T. S., Redeker, A. G. and Kanel G. C. (1991). Acetaminophen, isoniazid, and hepatic toxicity, Ann. Intern. Med. 114, 431.
Moxley, T. E., Royer, G. L., Hearron M. S., et al. (1975). Ibuprofen verus buffered phenylbutazone in the treatment of osteoarthritis: double-blind trial, J. Am. Ger. Soc. 23, 343–349.
Mucklow, J. C., Fraser, H. S., Bulpitt, C. J., et al. (1980). Environmental factors affecting paracetamol metabolismon London factory and office workers, Br. J. Clin. Pharmacol. 10, 67–74.
Mullen, B. J. (1987). Results of a six-month study comparing the safety and efficacy of nabumetone and aspirin in the treatment of osteoarthritis, Am. J. Med. 83, 74–77.
Muller, F. O., Gosling, J. A. and Erdmann, G. H. (1977). A comparison of tolmetin with aspirin in the treatment of osteo-arthritis of the knee, South African Medical Journal 51, 794–796.
Müller-Fassbender, H. (1987). Double-blind clinical trial of S-adenosylmethionine versus ibuprofen in the treatment of osteoarthritis, Am. J. Med. 83, 81–83.
Murphy, R., Swartz, R. and Watkins, P. B. (1990). Severe acetaminophentoxicity in a patient receiving isoniazid, Ann. Inter. Med. 113, 799–800.
Myers, S. L. (1999). Synovial fluid markers in osteoarthritis, Rheum. Dis. Clinics North Amer. 25, 433–449.
Myers, S. L., Dines, K., Brandt, D. A., et al. (1995). Assessment by high frequency ultrasound of articular cartilage thickness and osteoarthritic changes, J. Rheumatol. 22, 109–116.
Naylor, C. D. and Williams, J. I. (1996). Primary hip and knee replacement surgery: Ontario criteria for case selection and surgical priority, Quality of Health Care 5, 20–30.
Needleman, P. and Isakson, P. C. (1997). The discovery and function of COX-2, J. Rheumatol. 24 (Suppl. 49), 6–8.
Newman, N. M. and Ling, R. S. (1985). Acetabular bone destruction related to non-steroidal anti-infl ammatory drugs, Lancet 2, 11–14.
Newman, S. P. (1997). Psychosocial measures in musculoskeletal trials, J. Rheumatol. 24, 979–984.
Nimmo, J., Heading, R. C., Tothill, P., et al. (1973). Pharmacological modification of gastric emptying effects of propantheline and metoclopromide on paracetamol absorption, Br. Med. J. 1, 587–589.
Nimmo, W. S., Heading, R. C., Wilson, J., et al. (1975a). Inhibition of gastric emptying and drug absorption by narcotic analgesics, Br. J. Clin. Pharmacol. 2, 509–513.
Nimmo, W. S., Wilson, J. and Prescott, L. F. (1975b). Narcotic analgesics and delayed gastric emptying during labour, Lancet 1, 890–893.
Nolan, C. M., Sandbloom, R. E., Thummel, K. E., et al. (1994). Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis, Chest 105, 408–411.
Nolan, L. and O'Malley, K. (1988). Prescribing for the elderly. Part II. Prescribing patterns: differences due to age, J. Am. Geriatric Soc. 36, 245–254.
Nuki, G. (1983). Non-steroidal analgesics and anti-inflammatory agents, Brit. Med. J. 287, 39–43.
Nuki, G. (1990). Pain control and the use of non-steroidal anti-inflammatory drugs, Br. Med. Bull. 308, 262–278.
Nuki, G., (1993). The effects of non-steroidal anti-inflammatory drugs on cartilage and connective tissue, in: Intermittent High Intensity Exercise, D. A. D. Macleod, R. J. Maughan, C. Williams, C. R. Madeley, C. J. M. Sharp and R. W. Hutton (Eds), pp. 339–351. E and FN Spon, London.
Nuki, G., Downie, W. W., Dick, W. C., et al. (1973). Clinical trial of pentazocine in rheumatoid arthritis. Observations in the values of potent analgesics and placebos, Ann. Rheum. Dis. 32, 436–443.
O'Brien, W. M. and Bagby, G. F. (1985). Rare adverse reactions to nonsteroidal anti-inflammatory drugs, J. Rheumatol. 12, 562–567.
O'Callaghan, C. A., Andrews, P. A. and Ogg, C. S. (1994). Renal disease and use of topical non-steroidal anti-inflammatory drugs, Br. Med. J. 308, 110–111.
O'Reilly, S. C., Muir, K. R. and Doherty, M. (1996). Screening for pain in knee osteoarthritis: which question?, Ann. Rheum. Dis. 55, 931–933.
O'Reilly, S. C., Muir, K. R. and Doherty, M. (1999). Effectiveness of home exercise on pain and disability from osteoarthritis of the knee: a randomized controlled trial, Ann. Rheum. Dis. 58, 15–19.
Ogata, K., Yasunaga, M. and Nomiyama, H. (1997). The effect of wedged insoles on the thrust of osteoarthritic knees, Int. Orthopaed. 21, 308–312.
Ouslander, J. G. (1981). Drug therapy in the elderly, Ann. Int. Med. 95, 711–722.
Pahor, M., Guralnik, J. M., Wan, J Y., et al. (1999). Lower body osteoarthritis pain and dose of analgesic medications in older disabled women: The Women's Health and Aging Study, Am. J. Public. Health 89, 930–934.
Palmoski, M. J., Colyer, R. and Brandt, K. D. (1980). Marked suppression by salicylate of the augmented proteoglycan synthesis in osteoarthritic cartilage, Arthritis Rheum. 23, 83–91.
Pariet, M., Van Ryn, J., Mauz, A., et al. (1997). Differential inhibitors of COX-1 and COX-2 by NSAIDs: a summary of results obtainedusing various test systems, in: Selective COX-2 Inhibitors: Pharmacology, Clinical Effects and Therapeutic Potential, J. Vane and J. Botting (Eds), Vol. 3, pp. 27–46. Kluwer Academic Publishers, Dordrecht.
Parr G., Darekar B., Fletcher A., et al. (1989). Joint pain and quality of life; results of a randomised trial, Br. J. Clin. Pharmacol. 27, 235–242.
Patterson, R., Bello, A. E. and Lefkowith, J. (1999). Immunologic tolerability profile of celecoxib, Clin. Ther. 21(12), 2065–2079.
Pelletier, J. P., Mineau, F., Raynaud, J. P., et al. (1994). Intra articular injections with methylpred-nisolone acetate reduce osteoarthritic lesions in parallel with chondrocyte stromelysin synthesis in experimental osteoarthritis, Arthritis Rheum. 37, 414–423.
Pelletier, J. P., Caron, J. P., Evans, C., et al. (1997). In Vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy, Arthritis Rheum. 40, 1012–1019.
Pelletier, J. P., Martel-Pelletier, J., Abramson, S. B., et al. (2001). Osteoarthritis, an inflammatory disease. Potential implication for the selection of new therapeutic targets, Arthritis Rheum. 44, 1237–1247.
Perucca, E. and Richens, A. (1979). Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs, Br. J. Pharmacol. 7, 201–206.
Peterson, M. G. E., Kovar-Toledano, P. A., Otis, J. C., et al. (1993). Effect of a walking program on gait characteristics in patients with osteoarthritis, Arthritis Care Res. 6, 11–16.
Peterson, W. L. and Cryer, B. (1999). COX-1 sparing NSAIDs — is the enthusiasmjustified?, J. Am. Med. Assoc. 282, 1961–1963.
Peyron, J. G. (1982). Double-blind comparative studies of tiaprofenic acid in degenerative joint diseases, J. Rheum. 7, 151–158.
Pfeiffer, R. F. (1982). Drugs for pain in the elderly, Geriatrics 37, 67–76.
Picot, D., Loll, P. J. and Garraviot, R. M. (1994). The x-ray crystal structure of the membrane protein prostaglandinH2 synthase-1, Nature 367, 243–249.
Pipitone, V., Carrozzo, M. and Loizzi, P. (1973). A clinical study of Brufen in comparison with phenylbutazone and indomethacin. Abstracts of XIII International Congress of Rheumatology, Kyoto, p. 134.
Pirotte, J. H. (1984). Apparent potentiation by phenobarbital of hepatoxicity from small doses of acetaminophen, Ann. Inter. Med. 101, 403.
Poole, A. R. (1994). Immunochemical markers of joint inflammations, skeletal damage and repair: where are we now?, Ann. Rheum. Dis. 53, 3–5.
Prescott, L. F., Critchlely, J. A. J. H., Balali-Mood, M., et al. (1981). Effects of microsomal induction on paracetamol metabolism in man, Br. J. Clin. Pharmacol. 12, 149–153.
Preston S. J., Arnold, M. H., Beller, E. M., et al. (1989). Comparative analgesic and anti-inflammatory properties of sodium salicylate and acetyl salicylic acid (aspirin) in rheumatoid arthritis, Br. J. Clin. Pharmacol. 27, 607–611.
Puett, D. W. and Griffin, M. R. (1994). Published trials of nonmedical and noninvasive therapies for hip and knee osteoarthritis, Ann. Intern. Med. 121, 133–140.
Rashad, S., Revell, P., Hemingway, A., et al. (1989). Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis, Lancet 2, 519–522.
Ratcliffe, A. and Seibel, M. J. (1990). Biochemical markers in osteoarthritis, Curr. Opin. Rheumatol. 2, 770–776.
Ravaud, P., Moulinier, L., Giraudeau, B., et al. (1999). Effects of joint lavage and steroid injection in patients with osteoarthritis of the knee: results of multicenter, randomized, controlled trial, Arthritis Rheum. 42, 475–482.
Reddi, A. H. (1992). Regulation of cartilage and bone differentiationby bone morphogenetic proteins, Curr. Opin. Cell Biol. 4, 850–855.
Rennie, J. A. N., Mason, D. I. R. and Capell, H. A. (1977). Simple analgesics in rheumatoid arthritis. Editorial, Scot. Med. J. 22, 253–254.
Richter, J. A., Runge, L. A., Pinals, R. S., et al. (1980). Analysis of treatment terminators with gold and antimalarial compounds in RA, J. Rheumatol. 7, 153–159.
Riendeau, D., Percival, M. D., Brideau, C., et al. (2001). Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2, J. Pharmacol. Exp. Ther. 296(2), 558–566.
Rinder, H. M., Gagnier, R. P., Souhrada, M., et al. (2001). Bleeding time and platelet function in normal volunteers receiving meloxicam. Abstract, EULAR.
Roberts, M. S. and Cross, S. E. (1999). Percutaneous absorption of topically applied NSAIDs and other compounds: Role of solute properties, skin physiology and delivery systems, Inflammopharmacology 7, 339–350.
Robertson, D. R. C., Higginson, I., Macklin, B. S., et al. (1991). The influence of protein-containing meals on the pharmacokinetics of levodopa in healthy volunteers, Br. J. Clin. Pharmacol. 31, 413–417.
Rogers, S. M., Back, D. J., Stevenson, P., et al. (1987). Paracetamol intervention with oral contra-ception steroids: increased plasma concentration of ethinyloestradiol, Br. J. Clin. Pharmacol. 23, 721–725.
Rosenbloom D., Brooks, P., Bellamy, N., et al. (1985). Clinical Trials in the Rheumatic Diseases, Praeger, New York.
Ross, A. C. (1991). Infected arthroplasties, Curr. Opin. Rheumatol. 3, 628–633.
Roth, S. H. (1998). Efficacy and safety of tramadol HCl in breakthrough musculoskeletal pain attributed to osteoarthritis, J. Rheumatol. 25, 1358–1363.
Rothstein, J. (1975). Phenylbutazone and aspirin in osteoarthritis — a controlled study, Curr. Ther. Res. 17, 444–451.
Rovati, L. C. (1992). Clinical research in osteoarthritis: design and results of short-termand long-term trials with disease-modifying drugs, Int. J. Tissue Reactions 14, 243–251.
Rubin, R. N., Mentzer, R. L. and Budzynski, A. Z. (1984). Potentiation of anticoagulant effect of warfarin by acetaminophen (Tylenol), Clin. Res. 32, 698.
Ryan, M. E., Greenwald, R. A. and Golub, L. M. (1996). Potential of tetracyclines to modify cartilage breakdown in osteoarthritis, Curr. Opin. Rheumatol. 8, 238–247.
Saag, K., Fisher, C., McKay, J., et al. (1998). MK-0966, a specific COX-2 inhibitor, has clinical efficacy, comparable to Ibuprofen in the treatment of knee and hip OA in a 6-week controlled clinical trial, Arth. Rheum. 41 (Suppl. 9), 584.
Sacchetti, G., DiMurro, R., Mandelli, V., et al. (1978). Clinical testing of indoprofen in osteoarthritis: a controlled trial using a balanced incomplete block design, Curr. Ther. Res. 24, 274–283.
Sackett, D. L., Richardson, W. S., Rosenberg, W., et al. (1998). Evidence-Based Medicine. Churchill Livingstone, Edinburgh.
Sanha, O. and Liang, M. H. (1995). Assessment outcomes of clinical drug trials in osteoarthritis, Curr. Opin. Rheumatol. 7, 352–355.
Scale, D., Wobig, M. and Wolpert, W. (1994). Viscosupplementation of osteoarthritic knees with hylan: a treatment schedule study, Curr. Ther. Res. 55, 220–232.
Scharf, Y., Nahir, M., Schapera, D., et al. (1982). A comparative study of naproxen with diclofenac sodiumin osteoarthritis of the knee, Rheumatol. Rehabil. 21, 167–170.
Scharff, U. (1974). A double-blind comparison of phenylbutazone and aspirin in osteoarthritis, Curr. Ther. Res. 16, 1264–1269.
Scheiman, J. M. (1994). NSAID-induced peptic ulcer disease: a critical review of pathogenesis and management, Dig. Dis. 12(4), 210–222.
Scheiman, J. M., Behler, E. M., Loeffler, K. M., et al. (1994). Omeprozole ameliorates aspirin-induced gastrointestinal injury, Dig. Dis. and Sci. 39, 97–103.
Schilke, J. M., Johnson, G. D., Housh, T. J., et al. (1996). Effects of muscle-strength training on the functional status of patients with osteoarthritis of the knee joint, Nurs. Res. 45, 68–72.
Schnitzer, T. J., Kamin, M., Olson, W. H. (1999a). Tramadol allows reduction of naproxen dose among patients with naproxen-responsive osteoarthritis pain: a randomized, double-blind, placebo-controlled study, Arthritis Rheum. 42, 1370–1377.
Schnitzer, T. J., Truitt, K., Fleischmann, R., et al. (1999b). The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group. Clinical Therapeutics 21, 1688–1702.
Schoen, R. T. and Vender, R. J. (1989). Mechanisms of non-steroidal anti-inflammatory drug-induced gastric damage, Am. J. Med. 86, 449–458.
Schoenfeld, P. (1999). Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials, Am. J. Med. 107(6A), 49S–53S.
Scott, D. L., Berry, H., Capell, H., et al. (2001). The long term effects of non-steroidal anti-infl ammatory drugs in osteoarthritis of the knee: a randomized placebo-controlled trial, Rheumatology 39, 1095–1101.
Seef, L. B., Cuccherinin, B. A. and Zimmerman, H. J. (1986). Acetaminophen hepatotoxicity in alcoholics, Ann. Int. Med. 104, 399–404.
Seideman, P. and Melander, A. (1988). Equianalgesic effects of paracetamol and indomethacin in rheumatoid arthritis, Br. J. Rheumatol. 27, 117–122.
Sharma, S. C. and Feeley, J. (1996). The influence of aspirin and paracetamol on blood concentrations of alcohol in young adults, Br. Clin. Pharmacol. 41, 467P.
Sheng, H., Shao, J., Washington, M. K., et al. (2001). Prostaglandin E2 increases growth and motility of colorectal carcinoma cells, J. Biol. Chem. 276, 18075–18081.
Siegle, I., Klein, T., Backman, J. T., et al. (1998). Expression of cyclooxygenase-1 and cyclooxygenase-2 in human synovial tissue. Differential evaluation of cyclooxygenase-2 in in-fl ammatory joint diseases, Arthritis Rheum. 41(1), 122–129.
Sigthorsson, G., Tibble, J., Mahmaud, T., et al. (2000). NSAID-induced gastrointestinal damage:the biochemical consequences of the flion trappingflhypothesis, Inflammopharmacology 8, 31–41.
Silas, S. and Clegg, D. O. (1999). Selective COX-2 inhibition, Bull. Rheum. Dis. 48(2), 1–4.
Silverstein, F. E., Graham, D. Y., Senior, J. R., et al. (1995). Misoprostol reduces serious gastrointesti-nal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlledtrial, Ann. Intern. Med. 123, 241–249.
Silverstein, F. E., Faich, G., Goldstein, J. L., et al. (2000). Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritisand rheumatoid arthritis, the CLASS study: A randomised controlled trial. Celecoxib Long-term Arthritis Safety Study, JAMA 284, 1247–1255.
Simkin, P. A. and Bassett, J. E. (1995). Cartilage matrix molecules in serum and synovial fluid, Curr. Opin. Rheumatol. 7, 346–351.
Simmons, D. L., Botting, R. M., Robertson, P. M., et al. (1999). Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroidal-anti-inflammatory drugs, Proc. Natl. Acad. Sci. USA 16, 96 (6), 3275–3280.
Simon, L. S. (1999). Arthritis: new agents herald more effective symptom management, Geriatrics 54, 37–42.
Simon, L. S., Lanza, F. L., Lipsky, P. E., et al. (1998). Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor, Arth. Rheum. 41, 1591–1602.
Simon, L. S., Weaver, A. L., Graham, D. Y., et al. (1999). Anti-inflammatory and upper gastrointesti-nal effects of celecoxib in rheumatoid arthritis. A randomized controlled trial, J. Am. Med. Assoc. 282, 1921–1928.
Singh, G. and Ramey, D. R. (1998). NSAID induced gastrointestinal complications: the Aramis perspective, 1997, J. Rheumatol. 25, 8–16.
Situnayake, R. D., Grindulis, K. A. and McConkey, B. (1987). Long-term treatment of rheumatoid arthritis with sulphasalazine, gold, or penicillamine: a comparison using life-table methods, Ann. Rheum. Dis. 46, 177–183.
Slemenda, C., Brandt, K. D., Heilman, D. K., et al. (1997). Quadriceps weakness and osteoarthritis of the knee, Ann. Intern. Med. 127, 97–104.
Smith, J. B. and Willis, A. L. (1971). Aspirin selectivity inhibits prostaglandin production in human platelet, Chest 59, 12S.
Smith, W. L. and Marnett, L. J. (1991). Prostaglandin endoperoxide synthase: Structure and catalysis, Biochem. Biophys. Acta 1083, 1–17.
Smith, W. L., Garavito, R. M. and Dewitt, D. L. (1996). Prostaglandin endoperoxide H synthases (cyclooxygenase)-1and-2, J. Biol. Chem. 271, 33157–33160.
Solomon, L. (1973). Drug-induced arthropathy and necrosis of the femoral head, J. Bone Joint Surg. 55B, 246.
Somasundaram, S., Hayllar H., Rafi, S., et al. (1995). The biochemical basis of non-steroidal anti-infl ammatory drug-induced damage to the gastrointestinal tract: a review and a hypothesis, Scand. J. Gastroenterol. 30, 289–299.
Sorkin, E. M. and Brogden, R. N. (1985). Tiaprofenic acid. A review of its pharmacological efficacy in rheumatic diseases and pain states, Drugs 29, 208–235.
Sowers, M. F. and Lachance, L. (1999). Vitamins and arthritis. The roles of Vitamins A, C, D, and E, Rheum. Dis. Clinic N. Amer. 25, 315–344.
Spaziani, E. P., Lantz, M. E., Benoit, R. R., et al. (1996). The induction of cyclooxygenase-2(COX-2) in intact human amnion tissue by interluekin-4, Prostaglandins 51, 215–223.
Spector, T. D., Hart, D. J. and Nandra, D. (1997). Low level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease, Arthritis Rheum. 40, 723–727.
Steinbrocker, O., Traeger, C. H. and Batterman, R. C. (1949). Therapeutic criteria in rheumatoid arthritis, JAMA 140, 659–662.
Stern, A. I., Hogan, D. L., Kahn, L. H., et al. (1984). Protective effect of acetaminophen against aspirin and ethanol induced damage to the human gastric mucosa, Gastroenterology 86, 728–733.
Stillman, M. T., Napier, J. and Blackshear, J. L. (1984). Adverse effects of nonsteroidal anti-infl ammatory drugs on the kidney, Med. Clin. N. Am. 68, 371–385.
Tannenbaum, H., Davis, P., Russell, A. S., et al. (1996). An evidence-based approach to prescribing NSAIDs in musculoskeletal disease: a Canadian consensus. Canadian NSAID Consensus Partici-pants.
Tanojo, H., Wester, R. C., Shainhouse, J. Z., et al. (1999). Diclofenac metabolic profile following in vitro percutaneous absorption through viable human skin, Eur. J. Drug Metab. Pharmacokinet. 24(4), 345–351.
The Cooperating Clinic Committee of the American Rheumatism Association (1965). A seven day variability study of 499 patients with peripheral rheumatoid arthritis, Arth. Rheum. 8, 302–334.
Thecler, R., Sangha, O., Schaeren, S. et al. (1999). Superior responsiveness of the pain and function sections of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). as compared to the Lequesne-Algofunctional Index in patients with osteoarthritis of the lower extremities, Osteoarthritis Cartilage 7, 515–519.
Thomas, M., Michael, M. F., Andrew, P., et al. (1988). A study to investigate the effects of ranitidine on the metabolic disposition of paracetamol in man, Br. J. Clin. Pharmacol. 25, 671.
Thompson, P. W., Kirwan, J. R. and Barnes, G. G. (1985). Practical results of treatment with disease modifying anti-rheumatic drugs, Br. J. Rheumatol. 24, 167–175.
Toda, Y., Toda, T., Takemura, S., et al. (1999). Change in body fat, but not body weight or metabolic correlates of obesity, is related to symptomatic relief of obese patients with knee osteoarthritisafter a weight control program, J. Rheumatol. 25, 2181–2186.
Toth, P., Li, X., Lei, Z. M. et al. (1996). Expression of human chorionic gonadotropin (hCG)/ luteinizing hormone receptors and regulation of the cyclooxygenase-1 gene by exogenous hCG in human fetal membranes, J. Clin. Endrocinol. Metab. 81, 1283–1288.
Towheed, T. E. and Anastassiades, T. P. (2000). Glucosamine and chondroitin for treating symptoms of osteoarthritis: evidence is widely touted but incomplete, J. Amer. Med. Assoc. 283, 1483–1484.
Towheed, T. and Hochberg, M. (1996). Health-relatedquality of life after total hip replacement, Semin. Arthritis Rheum. 26, 483–491.
Towheed, T. E. and Hochberg, M. C. (1997). A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the knee, with an emphasis on trial methodology, Semin. Arthritis Rheum. 26, 755–770.
Trautman, M. S., Edwin, S. S., Collmer, D., et al. (1996). Prostaglandin H synthase-2 in human gestational tissues: Regulation in amnion, Placenta 17, 239–245.
Tréves, R., Maheu, E. and Dreiser, R. L. (1995). Therapeutic trials in digital osteoarthritis. A critical review, Revue du Rhumatologiee English Edition 62 (Suppl.), 33S–41S.
Trials 020, 021, 054, 060, 071, 087. Data on file, G. D. Searle & Co.
Truitt, K., Ettinger, W., Schnitzert, T., et al. (1999). Rofecoxib, a COX-2 specific inhibitor, had clinical efficacy and overall safety in treating osteoarthritis patients aged 80 years and older, Ann. Rheum. Dis. (EULAR), Abstract 859.
Trummlitz, G. and Wittneben, H. (2001). Insight into the structural basis of selective cyclooxygenase-2 inhibition. Abstract, EULAR.
Tsoukas C., Eyster, E., Mukhopadhyay, S., et al. (2001). Efficacy of etoricoxib in the treatment of hemophilic arthropathy, Arthritis Rheum. 44 (Suppl. 9), abstract 429, S124.
Tyson, V. C. H. and Glynne, A. (1980). A comparative study of benoxaprofen and ibuprofen in osteoarthritis general practice, J. Rheum. 7 (Suppl.), 132–138.
Udall, J. A. (1978). Drug interference with warfarin therapy, Clin. Med. 77, 20.
Umbenhauer, E. R. (1983). Diflunisal in the treatment of the pain of osteoarthritis.Summary of clinical studies, Pharmacotherapy 3, 55S–60S.
Vaile J. H. and Davis P. (1998). Topical NSAIDs for musculoskeletal conditions. A review of the literature, Drugs 56, 783–799.
Valentini, M., Cannizzaro, R., Poletti, M., et al. (1995). Nonsteroidal anti-inflammatory drugs for can-cer pain: comparison between misoprostal and ranitidine win prevention of upper gastrointestinal damage, J. Clin. Oncol. 13, 2637–2642.
Valtonen, E. J. (1979a). Symptomatic response of osteoarthritis to benorylate. A dose discrimination study, Scand. J. Rheum. 25 (Suppl.), 9–14.
Valtonen, E. J. (1979b). Clinical comparisonof fenbufen and aspirin in osteoarthritis, Scand. J. Rheum. 27,(Suppl.) 1–7.
van Baar, M. E., Assendelft. W. J., Dekker, J., et al. (1999). Effectiveness of exercise therapy in patients with osteoarthritis of the hip and knee: a systemic review of randomized clinical trials, Arthritis Rheum. 42, 1361–1369.
van Ryn, J., Trummiltz, G. and Pairet, M. (2000). COX-2 selectivity and inflammatory processes, Curr. Med. Chem. 7, 1145–1161.
Vane, J. R. (1971). Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs, Nature 231, 232–235.
Vestal, R. E. (1978). Non-steroidal analgesic and anti-inflammatory agents, Br. Med. J. 287, 39–43.
Vignon, E., Mathieu, P., Broquet, P., et al. (1990). Cartilage degradative enzymes in human osteoarthritis: effect of a nonsteroidal anti-inflammatory drug administered orally, Semin. Arthritis Rheum. 19 (Suppl. 1), 26–29.
Wagner, J. A., Kraft, W., Burke, J., et al. (2001). The COX-2 inhibitor etoricoxib did not alter the anti-platelet effects of low-dose aspirin in healthy volunteers, Arthritis Rheum. 44 (Suppl. 9), abstract 498, S135.
Wagenhauser, F. J. (1973). Long-term study with Brufen, Abstracts of XIII International Congress of Rheumatology, Kyoto, p. 106.
Waldschmidt, J. G., Braunstein, E. M. and Buckwalter, K. A. (1999). Magnetic resonance imaging of osteoarthritis, Rheum. Dis. Clinics North Amer. 25, 451–465.
Wallace, J. L. (1996). NSAID gastroenteropathy: past, present and future, Canad. J. Gastroenterol. 10, 451–459.
Ware, J., et al. (1993). SF-36 manual and interpretation guide. The Health Institute, Boston, Massachusetts.
Warner, T. D., Giuliano, F., Vojnovic, I., et al. (1999). Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis, Proc. Natl. Acad. Sci. USA 96, 7563–7568.
Watson, C. P. (1994). Topical capsaicin as an adjuvant analgesic, J. Pain Symptom Management 9, 425–433.
Watson, D. J., Harper, S., Shao, P., et al. (1999). Lower incidence of GI-related discontinuation and 'NSAID-type' symptoms in patients treated with rofecoxib versus non-specific cyclooxygenase inhibitors, Ann. Rheum. Dis. (EULAR) Abstract 863.
Weinberger, M., Tierney, W. M., Booker, P., et al. (1989). Can the provision of information to patients with osteoarthritis improve functional status? A randomized controlled trial, Arthritis Rheum. 32, 1577–1583.
Wessela, J. C., Koelman, H. A., Boneschans, B., et al. (1992). The influence of different types of breakfast on the absorption of paracetamol among members of an ethnic group, Int. J. Clin. Pharmacol. Ther. Toxicol. 30, 208–213.
Whitcomb, D. C. and Block, G. D. (1994). Association of acetaminophen hepatotoxicity with fasting and ethanol use, J. Am. Med. Assoc. 272, 1845–1850.
Wilhelmsen, L., Ljungberg, S., Wedel, H., et al. (1976). Comparison between participants in primary preventative trials, J. Chronic Dis. 29, 331–339.
Williams, H. J., Ward, J. R., Egger, M. J., et al. (1993). Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee, Arthritis Rheum. 36, 1196–1206.
Wilson, J. T., Kasantikul, V., Harbision, R., et al. (1978). Death in an adolescent following an overdose of acetaminophen and phenobarbital, Am. J. Dis. Child. 132, 466–473.
Wojtulewski, J. A., Walter, J. and Gray, J. (1978). Diflunisal compared with naproxen in the treatment of osteoarthritis of hip or knee — a double-blind trial, Curr. Med. Res. Opin. 5, 562–566.
Wolf, M. M. (1996). NSAIDs and the gastrointestinal mucosa, Hospital Practice 31(12), 37–44, 47–48.
Wollheim, F. A. (1999). Serum markers of articular cartilage damage and repair, Rheum. Dis. Clinics North Amer. 25, 417–432.
Yamagata, K., Andreasson, K. I., Kaufman, W. E., et al. (1993). Expression of a mitogen-inducible cyclooxygenase in brain neurons; regulation by synaptic activity and glucocorticoids, Neuron 11, 371–386.
Yang, T., Singh, I., Pham, H., et al. (1997). Regulation of cyclooxygenase expression in the kidney by dietary salt intake, Am. J. Physiol. 274, F481–F489.
Yeomans, N. D., Tulassay, Z., Juhasz, L., et al. (1998). A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs, New Engl. J. Med. 338, 719–726.
Yip, A. S., Chow, W. H., Tai, Y. T., et al. (1990). Adverse effect of topical methylsalicylate ointment on warfarin anticoagulation: an unrecognized potential hazard, Postgrad. Med. J. 66, 367–369.
Yocum, D., Fleischmann, R., Dalgin, P., et al. (2000). Efficacy and safety of meloxicam in the treatment of osteoarthritis, Arch. Int. Med. 160, 2947–2954.
Ytterberg, S. R., Mahowald., M. L. and Woods, S. R. (1998). Codeine and oxycodone use in patients with chronic rheumatic disease pain, Arthritis Rheum. 41, 1603–1612.
Zakar, T., Hirst, J. J., Milovic, J. E., et al. (1995). Glucocorticoids stimulate the expression of prostaglandin endoperoxide H synthase-2 in amnion cells, Endocrinology 136, 1610–1619.
Zhang, W. Y. and LiWanPo, A. (1994). The effectiveness of topically applied capsaicin. A meta-analysis, Eur. J. Clin. Pharmacol. 46, 517–522.
Zimmerman, H. J. and Maddrey, W. C. (1995). Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure, Hepatology 22, 767–773.
Rights and permissions
About this article
Cite this article
Buchanan, W.W., Kean, W.F. Osteoarthritis IV: Clinical therapeutic trials and treatment. Inflammopharmacology 10, 79–155 (2002). https://doi.org/10.1163/156856002320752017
Issue Date:
DOI: https://doi.org/10.1163/156856002320752017